Business
Theriva Biologics Provides Response to Unusual Market Action
ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today that the Company had become aware of unusual trading activity in its common stock on the NYSE American (the “NYSE”) on October 24, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company
About this update from Theriva Biologics, Inc.
[{"type":"image","alt":"Theriva Biologics, Inc.","displaySize":"","headline":null,"caption":"Theriva Biologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NwCW1pyw7ahIW1qecrDFNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a","width":300,"height":102}},"lazy":false},{"type":"text","content":"ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today that the Company had become aware of unusual trading activity in its common stock on the NYSE American (the “NYSE”) on October 24, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company Guide. The Company has made inquiries and does not believe corrective actions are appropriate. The Company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action. However, on October 13, 2025, the Company announced the presentation of expanded data from its VIRAGE trial investigating VCN-01 at a mini oral session at the European Society for Medical Oncology (ESMO 2025) Annual Congress.","length":1032,"tagName":"p"},{"type":"text","content":"About Theriva™ Biologics, Inc.","length":30,"tagName":"p"},{"type":"text","content":"Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidates are: (1) VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designe...